AEROVATE THERAPEUTICS INC's ticker is AVTE and the CUSIP is 008064107. A total of 52 filers reported holding AEROVATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,271,540 | -20.9% | 756,930 | 0.0% | 0.22% | -7.2% |
Q2 2023 | $12,981,350 | -15.0% | 756,930 | 0.0% | 0.24% | -21.7% |
Q1 2023 | $15,267,278 | -31.4% | 756,930 | -0.3% | 0.30% | -29.6% |
Q4 2022 | $22,254,522 | +68.8% | 759,540 | -4.5% | 0.43% | +73.9% |
Q3 2022 | $13,181,000 | +76.2% | 795,000 | +66.1% | 0.24% | +80.1% |
Q2 2022 | $7,480,000 | -20.0% | 478,579 | -6.2% | 0.14% | -10.5% |
Q1 2022 | $9,347,000 | +48.0% | 509,949 | -4.8% | 0.15% | +87.7% |
Q4 2021 | $6,316,000 | -43.8% | 535,714 | 0.0% | 0.08% | -34.7% |
Q3 2021 | $11,239,000 | -8.1% | 535,714 | 0.0% | 0.12% | 0.0% |
Q2 2021 | $12,230,000 | – | 535,714 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
OUP Management Co., LLC | 603,762 | $8,193,050 | 18.42% |
TCG Crossover Management, LLC | 2,201,274 | $29,871,288 | 4.40% |
Atlas Venture Life Science Advisors, LLC | 2,039,249 | $27,672,609 | 4.29% |
Sofinnova Investments, Inc. | 3,758,686 | $51,005,369 | 3.22% |
GREAT POINT PARTNERS LLC | 1,091,233 | $14,808,032 | 2.70% |
RA Capital Management | 8,263,982 | $112,142,236 | 2.21% |
Cormorant Asset Management, LP | 1,561,696 | $21,192,215 | 1.24% |
Frazier Life Sciences Management, L.P. | 1,204,867 | $16,350,045 | 1.09% |
Octagon Capital Advisors LP | 497,370 | $6,749,311 | 1.04% |
Ghost Tree Capital, LLC | 201,197 | $2,730,243 | 0.90% |